383 related articles for article (PubMed ID: 10780867)
1. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
[TBL] [Abstract][Full Text] [Related]
2. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
Chavassieux PM; Arlot ME; Reda C; Wei L; Yates AJ; Meunier PJ
J Clin Invest; 1997 Sep; 100(6):1475-80. PubMed ID: 9294113
[TBL] [Abstract][Full Text] [Related]
3. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis.
Dalle Carbonare L; Arlot ME; Chavassieux PM; Roux JP; Portero NR; Meunier PJ
J Bone Miner Res; 2001 Jan; 16(1):97-103. PubMed ID: 11149495
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
[TBL] [Abstract][Full Text] [Related]
6. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
[TBL] [Abstract][Full Text] [Related]
7. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
[TBL] [Abstract][Full Text] [Related]
8. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
9. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
[TBL] [Abstract][Full Text] [Related]
10. Effects of bisphosphonates on matrix mineralization.
Boivin G; Meunier PJ
J Musculoskelet Neuronal Interact; 2002 Dec; 2(6):538-43. PubMed ID: 15758388
[TBL] [Abstract][Full Text] [Related]
11. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment.
Rudge S; Hailwood S; Horne A; Lucas J; Wu F; Cundy T
Rheumatology (Oxford); 2005 Jun; 44(6):813-8. PubMed ID: 15695300
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
13. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
14. Alendronate influences bending force of femoral diaphysis after orchidectomy in rats.
Huuskonen J; Arnala I; Olkkonen H; Alhava E
Ann Chir Gynaecol; 2001; 90(2):109-14. PubMed ID: 11459259
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid treatment of ovariectomized sheep affects mineral density, structure, and mechanical properties of cancellous bone.
Schorlemmer S; Gohl C; Iwabu S; Ignatius A; Claes L; Augat P
J Bone Miner Res; 2003 Nov; 18(11):2010-5. PubMed ID: 14606514
[TBL] [Abstract][Full Text] [Related]
16. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
[TBL] [Abstract][Full Text] [Related]
17. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids.
Vedi S; Elkin SL; Compston JE
Calcif Tissue Int; 2005 Aug; 77(2):79-83. PubMed ID: 16086108
[TBL] [Abstract][Full Text] [Related]
18. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
19. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
Allen MR; Iwata K; Phipps R; Burr DB
Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
[TBL] [Abstract][Full Text] [Related]
20. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
